Genentech, Inc. - Product Pipeline Review - 2016

Date: February 24, 2016
Pages: 128
Price:
US$ 1,500.00 US$ 1,275.00
Offer valid until December 31, 2016!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: G01841301DBEN
Leaflet:

Download PDF Leaflet

Genentech, Inc. - Product Pipeline Review - 2016

SUMMARY

Global Markets Direct’s, ‘Genentech, Inc. - Product Pipeline Review - 2016’, provides an overview of the Genentech, Inc.’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Genentech, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

SCOPE
  • The report provides a snapshot of the pipeline therapeutic landscape of Genentech, Inc.
  • The report provides overview of Genentech, Inc. including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Genentech, Inc.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Genentech, Inc.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects
REASONS TO BUY
  • Evaluate Genentech, Inc.’s strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Genentech, Inc.
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Genentech, Inc.’s pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Genentech, Inc. Snapshot
Genentech, Inc. Overview
Key Information
Key Facts
Genentech, Inc. - Research and Development Overview
Key Therapeutic Areas
Genentech, Inc. - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
Pipeline Products - Partnered Products
Pipeline Products - Out-Licensed Products
Genentech, Inc. - Pipeline Products Glance
Genentech, Inc. - Late Stage Pipeline Products
Genentech, Inc. - Clinical Stage Pipeline Products
Genentech, Inc. - Early Stage Pipeline Products
Genentech, Inc. - Drug Profiles
crenezumab
etrolizumab
lampalizumab
taselisib
duligotuzumab
ipatasertib
polatuzumab vedotin
quilizumab
RG-6046
RG-7745
BFKB-8488A
BTCT-4465A
DMUC-4064A
Drug for Inflammatory Diseases
DSTA-4637S
GDC-0134
GDC-0927
lifastuzumab vedotin
RG-6024
RG-6029
RG-7741
RG-7828
RG-7842
RG-7845
RG-7882
RG-7888
RG-7893
CS-3
G-007LK
G-244LM
GNE-293
GNE-317
GNE-3511
GNE-555
GNE-7915
GNE-892
MAb-30D8
Monoclonal Antibodies to Target CD98hc and BACE for Alzheimer's Disease
Monoclonal Antibody Conjugate for B-Cell Non Hodgkin's Lymphoma
Monoclonal Antibody Conjugates for Oncology
Monoclonal Antibody to Inhibit HtrA1 for Age Related Macular Degeneration
Monoclonal Antibody to Inhibit Tau for Alzheimer's Disease and Neurodegenerative Disorders
MV-1
pictilisib
Small Molecule to Inhibit BACE1 for Alzheimer’s Disease
Small Molecule to Inhibit MAP4K4 for Cancer
Small Molecule to Inhibit TYK2 for Psoriasis and IBD
Small Molecules to Inhibit IRAK4 for Immunology and Oncology
Small Molecules to Inhibit JAK2 for Cancer
Small Molecules to Inhibit JAK2 for Myeloproliferative Neoplasms
Small Molecules to Inhibit Lactate Dehydrogenase for Lung Adenocarcinoma
Small Molecules to Inhibit NAMPT for Cancer
Small Molecules to Inhibit PI3-Kinase Delta for Inflammatory and Leukocyte Disorders
Monoclonal Antibody Conjugated for Cancer
Small Molecule 2 for Undisclosed Indication
Small Molecule to Inhibit ITK for Asthma
Small Molecules 1 for Undisclosed Indication
Small Molecules for Central Nervous System Disorders
Small Molecules for Undisclosed Indication
Small Molecules to Antagonize RORc for Autoimmune Diseases and Inflammation
Small Molecules to Inhibit EGFR for Non-Small Cell Lung Cancer
Small Molecules to Inhibit Jak1/2 for Hematopoietic and Immunologic diseases
Small Molecules to Inhibit Ubiquitin Specific Protease for Oncology
Genentech, Inc. - Pipeline Analysis
Genentech, Inc. - Pipeline Products by Target
Genentech, Inc. - Pipeline Products by Route of Administration
Genentech, Inc. - Pipeline Products by Molecule Type
Genentech, Inc. - Pipeline Products by Mechanism of Action
Genentech, Inc. - Recent Pipeline Updates
Genentech, Inc. - Dormant Projects
Genentech, Inc. - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
Genentech, Inc. - Company Statement
Genentech, Inc. - Locations and Subsidiaries
Head Office
Other Locations & Subsidiaries
Genentech, Inc. - Key Manufacturing Facilities
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Genentech, Inc., Key Information
Genentech, Inc., Key Facts
Genentech, Inc. - Pipeline by Indication, 2016
Genentech, Inc. - Pipeline by Stage of Development, 2016
Genentech, Inc. - Monotherapy Products in Pipeline, 2016
Genentech, Inc. - Partnered Products in Pipeline, 2016
Genentech, Inc. - Partnered Products/ Combination Treatment Modalities, 2016
Genentech, Inc. - Out-Licensed Products in Pipeline, 2016
Genentech, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2016
Genentech, Inc. - Phase III, 2016
Genentech, Inc. - Phase II, 2016
Genentech, Inc. - Phase I, 2016
Genentech, Inc. - Preclinical, 2016
Genentech, Inc. - Discovery, 2016
Genentech, Inc. - Pipeline by Target, 2016
Genentech, Inc. - Pipeline by Route of Administration, 2016
Genentech, Inc. - Pipeline by Molecule Type, 2016
Genentech, Inc. - Pipeline Products by Mechanism of Action, 2016
Genentech, Inc. - Recent Pipeline Updates, 2016
Genentech, Inc. - Dormant Developmental Projects,2016
Genentech, Inc. - Discontinued Pipeline Products, 2016
Genentech, Inc., Other Locations
Genentech, Inc., Key Manufacturing Facilities

LIST OF FIGURES

Genentech, Inc. - Pipeline by Top 10 Indication, 2016
Genentech, Inc. - Pipeline by Stage of Development, 2016
Genentech, Inc. - Monotherapy Products in Pipeline, 2016
Genentech, Inc. - Partnered Products in Pipeline, 2016
Genentech, Inc. - Out-Licensed Products in Pipeline, 2016
Genentech, Inc. - Pipeline by Top 10 Target, 2016
Genentech, Inc. - Pipeline by Route of Administration, 2016
Genentech, Inc. - Pipeline by Molecule Type, 2016
Genentech, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2016
Skip to top


AnaptysBio, Inc. - Product Pipeline Review - 2015 US$ 1,200.00 Apr, 2015 · 24 pages
EGEN, Inc. - Product Pipeline Review - 2014 US$ 1,125.00 Jul, 2014 · 24 pages
GenSpera, Inc. - Product Pipeline Review - 2015 US$ 1,200.00 Aug, 2015 · 27 pages
ImmunoFrontier, Inc. - Product Pipeline Review - 2015 US$ 1,200.00 Jun, 2015 · 22 pages

Ask Your Question

Genentech, Inc. - Product Pipeline Review - 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: